"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

Pharmaceutical companies are always risky propositions. So much depends on drugs in the pipeline, FDA approvals, patents in effect, and things going well when the medicines are prescribed to the public at large. But they can also be profitable when you've invested at the right time, right place. I think it is the right time, right place when it comes to Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ). Jazz has figured out a model that is a bit less risky. Rather than trying to find the next big drug for something that other drug companies are also seeking cures for (think Alzheimer's or breast cancer), it focuses on those neurological and psychological needs that may be less high profile, yet are unmet by other medicines.

The FDA is nearing final approval of its lead compound, Luvox CR, which was developed by Jazz to treat obsessive compulsive disorder (OCD) and social anxiety disorder (SAD), two prevalent psychological disorders, and is expected to be released in 2008. In a July 11 research report, Lehman Brothers said, "We view Luvox CR as an attractive commercial opportunity for Jazz owing to the combination of: (1) a large, addressable patient population; (2) compelling clinical data including once-daily dosing; (3) a highly concentrated target physician audience; and (4) an absence of promoted brand products against which it will compete."

The latter point is the biggest one for me: Jazz is treading where other companies have not, and as a result, they will have a lock on a very viable landscape. Lehman Brothers expects Luvox CR sales to hit $170 million in 2011, and $230 million by 2015. If they are on target, and I believe they are, we will see Jazz increase significantly in value in the coming years, this upcoming year in particular, when Luvox CR is expected to hit the marketplace.

Continue reading Jazz Pharmaceuticals: Jazzed by its potential

Jazz Pharmaceuticals: Jazzed by its potential originally appeared on BloggingStocks on Thu, 26 Jul 2007 08:31:00 EST. Please see our terms for use of feeds.

Wall Street's equity market shifts into summer mode -- historically a lighter season -- with just three IPOs on the docket this week.

Those deals tentatively scheduled to price include:

IPOs:

Thursday

Amicus Therapeutics (FOLD), a 5M-share IPO for this gene-based medicine company. Morgan Stanley and Merrill Lynch are the lead managers. Filing range: $14.00-$16.00.

Friday

Jazz Pharmaceuticals (JAZZ), a 6M-share IPO for this pharmaceutical company. Morgan Stanley and Lehman Brothers are the lead managers. Filing range: $24.00-$26.00.

LDK Solar (LDK), a 17.384M-share IPO for this solar cells company. Morgan Stanley and UBS Investment are the lead managers. Filing range: $25.00-$27.00.

- -

For the latest market intelligence on IPOs, Syndicate, and after-market trades, check out The Fly Syndicate at www.theflyonthewall.com. [Subscription required.]

IPO & secondary preview -- Week of May 28, 2007 originally appeared on BloggingStocks on Tue, 29 May 2007 09:56:00 EST. Please see our terms for use of feeds.